ReviewFrontiers in oncology2015
Immunotherapeutic advancements for glioblastoma.
Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- Nanoparticle-Based Approaches for Glioblastoma Treatment: Advances and Future Prospects.CNS & neurological disorders drug targets · 2026Review
- Single center experience of IDH inhibitors in recurrent high-grade gliomas.Journal of neuro-oncology · 2025Article
- A Review of Artificial Intelligence-Based Systems for Non-Invasive Glioblastoma Diagnosis.Life (Basel, Switzerland) · 2025Review
- Insights into Healthcare Professionals' Perceptions and Attitudes toward Nanotechnological Device Application: What Is the Current Situation in Glioblastoma Research?Biomedicines · 2023Review
- Current Status and Challenges of Vaccination Therapy for Glioblastoma.Molecular cancer therapeutics · 2023Article
- A Conjugate between Lqh-8/6, a Natural Peptide Analogue of Chlorotoxin, and Doxorubicin Efficiently Induces Glioma Cell Death.Biomedicines · 2022Article
- Path-ATT-CNN: A Novel Deep Neural Network Method for Key Pathway Identification of Lung Cancer.Frontiers in genetics · 2022Article
- Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.Journal of hematology & oncology · 2021Review
- Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.Oncoimmunology · 2021Article
- Immuno-oncology: are TAM receptors in glioblastoma friends or foes?Cell communication and signaling : CCS · 2021Review
- Comprehensively investigating the expression levels and the prognostic role of transforming growth factor beta-induced (TGFBI) in glioblastoma multiforme.Translational cancer research · 2020Article
- Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.Frontiers in immunology · 2020Review
- PD-L1/PD-1 Axis in Glioblastoma Multiforme.International journal of molecular sciences · 2019Review
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.Molecular & cellular proteomics : MCP · 2019Article
- Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.Clinical epigenetics · 2019Article
- Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells.Journal of extracellular vesicles · 2019Article
- Harnessing the immune system in glioblastoma.British journal of cancer · 2018Review
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.Molecular & cellular proteomics : MCP · 2018Article
- Modeling tumor immunity of mouse glioblastoma by exhausted CD8Scientific reports · 2018Article
- Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.Journal for immunotherapy of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy seeks to improve the body's immune response to a tumor. Currently, the principal mechanisms employed are: (1) to improve an aspect of the immune response (e.g., T cell activation) and (2) to encourage the targeting of particular antigens. The latter is typically achieved by exposing the immune system to the antigen in question, in vivo, or in vitro followed by re-introduction of the primed cells to the body. The clinical relevance of these approaches has already been demonstrated for solid tumors such as melanoma and prostate cancer. The central nervous system was previously thought to be immune privileged. However, we know now that the immune system is highly active in the brain and interacts with brain tumors. Thus, harnessing and exploiting this interaction represents an important approach for treating malignant brain tumors. We present a summary of progress in this area, focusing particularly on immune-checkpoint inhibition, vaccines, and T cell engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.